Celldex Completes Phase 3 Enrollment for Barzolvolimab in Chronic Urticaria Trials
Key Facts
- •Celldex completed enrollment in the global Phase 3 program of barzolvolimab for chronic spontaneous urticaria (CSU).
- •1,939 patients were enrolled across 43 countries, making it the largest program in antihistamine refractory CSU.
- •The program consists of two global Phase 3 trials: EMBARQ-CSU1 and EMBARQ-CSU2.
Celldex Therapeutics (NASDAQ: CLDX) has successfully completed patient enrollment for its global Phase 3 clinical program evaluating barzolvolimab. The program, focused on treating chronic spontaneous urticaria (CSU), includes two pivotal trials, EMBARQ-CSU1 and EMBARQ-CSU2. A total of 1,939 patients across 43 countries were enrolled, representing the largest clinical program ever conducted for antihistamine-refractory CSU. This milestone is significant for the biotech firm as it establishes a clear path toward top-line data results and potential regulatory filing. Barzolvolimab aims to provide a new therapeutic option for patients who do not respond to standard antihistamine treatments. Investors view this progress as a reduction in execution risk for Celldex's lead drug candidate.
freemium.freemium.cta.signup
freemium.freemium.cta.signup_button